Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KB 407

Next Previous
Search
Drug Profile

KB 407

Alternative Names: KB-407

Latest Information Update: 04 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Class Antifibrotics; Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 19 Feb 2025 Cystic Fibrosis Foundation (CFF) Therapeutic Development Network (TDN) Clinical Research Executive Committee grants full sanctioning of the KB 407 phase I CORAL-1 study protocol
  • 10 Dec 2024 Adverse events data from a phase I trial in Cystic fibrosis released by Krystal Biotech
  • 29 Feb 2024 Krystal Biotech receives patent protection for patent application covering methods of using KB407 for the treatment of Cystic fibrosis and other diseases causing progressive lung destruction in South Africa

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top